Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.
September 07, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Adeoye “Oye” Olukotun, M.D. to its Board of Directors,...
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
August 30, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will...
Tonix Pharmaceuticals Announces Director Stepping Down
August 22, 2018 16:01 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Samuel Saks, M.D. has stepped down from the Company’s board of directors,...
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium
August 21, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Retrospective Analysis of the Discontinued Phase 3 P301 “HONOR” Study Revealed Clinically Meaningful Response to Tonmya in PTSD Participants with Trauma Experienced Within Nine Years Prior to...
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium
August 15, 2018 11:46 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3...
Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
August 13, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
HONOR Study Results to be Included in Poster Presentation at a Scientific Conference in August 2018 FDA Meeting in October 2018 Confirmed to Discuss New Phase 3 Study for Tonmya® in PTSD New Phase 3...
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD
July 27, 2018 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
HONOR Study will Stop due to Inadequate Separation from Placebo at Week-12 Results at Week-4 Demonstrated Meaningful Clinical Improvement Company Plans to Meet with FDA to Discuss Next Steps for...
Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease
July 16, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
May 31, 2018 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), presented data from the Phase 2 AtEase study of Tonmya®* (cyclobenzaprine HCl sublingual...
Tonix Pharmaceuticals to Present at the 2018 BIO International Convention
May 30, 2018 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will...